SUPPLEMENTARY MATERIAL

Supplementary Table 1. Bias assessment


		Patient selection		Index text		Reference standard		Time and flow
Authors	rs Y. of publ. Risk of bias Concerns about applicability		Risk of bias	Concerns about applicability	Risk of bias	Concerns about applicability	Risk of bias	
Imai et al.	2005	Low	Low	High	High	High	High	Low
Jovin et al.	2005	Low	Low	High	High	High	High	Low
Dabitz et al.	2007	Low	Low	High	High	High	High	Low
Papanagiotou et al.	2011	Low	Low	Low	Low	Low	Low	Low
Hajdukova et al.	2013	Low	High	High	High	High	High	Low
Dalyiai et al.	2013	Low	Unclear	High	High	High	High	Low
Mpotsaris et al.	2013	Low	Low	Low	Low	Low	Low	Low
Stampfl et al.	2014	Low	Low	Low	Low	Unclear	Low	Low
Tütüncü et al.	2014	Low	Low	Low	Low	Low	Low	Low
Lescher et al.	2014	Low	Low	Low	Low	Low	Low	Low
Heck et al.	2014	Low	Low	Low	Low	Low	Low	Low
Cohen et al.	2014	Low	Low	Low	Low	Low	Low	Low
Lockau et al.	2014	Low	Low	Low	Low	Low	Low	Low
Spiotta et al.	2014	Low	Low	High	Unclear	Low	Low	Low
Dababneh et al.	2014	Low	Low	High	Unclear	Low	Low	Low
Choi et al.	2014	Low	Low	Low	Low	Low	Low	Low
Behme et al.	2015	Low	Low	Low	Low	Low	Low	Low
Maurer et al.	2015	Low	Low	Low	Low	Low	Low	Low
Puri et al.	2015	Low	Low	Low	Low	Low	Low	Low

Steglich- Arnholm et al.	2015	Low	Low	Low	Low	Low	Low	Low
Yoon et al.	2015	Low	Low	Low	Low	Low	Low	Low
de Lucena et al.	2015	Low	Low	Low	Low	Low	Low	Low
Son et al.	2015	Low	Low	Low	Low	Low	Low	Low
Grigoryan	2016	Low	Low	High	Unclear	Low	Low	Low
Fahed	2016	Low	Low	High	Unclear	Low	Low	Low
Rangel- Castilla et al.	2017	Low	Low	Low	Low	Low	Low	Low
Sallustio et al.	2017	Low	Low	Low	Low	Low	Low	Low
Akpinar et al.	2017	Low	Low	Low	Low	Low	Low	Low
Mpotsaris et al.	2017	Low	Low	Low	Low	Low	Low	Low
Al-Mufti et al.	2017	Low	Low	Low	Low	Low	Low	Low
Mehta et al.	2018	Low	Low	High	Unclear	Low	Low	Low
Li et al.	2018	Low	Low	Low	Low	Low	Low	Low
Bartolini et al.	2018	Low	Low	Low	Low	Low	Low	Low
Sadeh-Gonik et al.	2018	Low	Low	High	Unclear	Low	Low	Low
Papanagiotou et al.	2018	Low	Low	Low	Low	Low	Low	Low
Maus et al.	2018	Low	Low	Low	Low	Low	Low	Low
Eker et al.	2018	Low	Low	Low	Low	Low	Low	Low
Wallocha et al.	2019	Low	Low	Low	Low	Low	Low	Low
Kang et al.	2019	Low	Low	Low	Low	Low	Low	Low
Jadhav et al.	2019	Low	Low	Low	Low	Low	Low	Low
Kim et al.	2020	Low	Low	Low	Low	Low	Low	Low
Garg et al.	2021	Low	Low	High	Unclear	Low	Low	Low


Bracco et al.	2021	Low	Low	High	Unclear	Low	Low	Low	
Li et al.	2021	Low	Low	Low	Low	Low	Low	Low	
Cirillo et al.	2021	Low	Low	Low	Low	Low	Low	Low	
Pop et al.	2022	Low	Low	Low	Low	Low	Low	Low	

Supplementary Figure 1. Funnel-plot for publication bias in studies included in meta-analysis for primary outcome.


No publication bias emerges from linear regression test for funnel plot asymmetry (p=0.53).



Supplementary Figure 2. Meta-analysis of proportions for mRS 0-2 in eCAS studies.



Supplementary Figure 3. Meta-analysis of proportions for mRS 0-2 in no stenting studies.



Supplementary Figure 4. Evolution over time of the comparison for mRS 0-2 depending on treatment paradigm.

Study	e Events	eCAS Total E	no ste Events		Odds Ratio	OR	95%-CI	Weight
Yearcutoff = 2005-2017								
Fahed 2016	18	37	15	33		1 14 10	.44; 2.91]	6.1%
Grigoryan 2016	28	67	14	33			.42; 2.27]	7.3%
Lescher 2014	3	9	11	30		-	.18: 4.16]	2.4%
Mpotsaris 2013	6	17	8	24	_		.30; 4.03]	3.3%
Tütüncü 2014	2	4	5	10	_		10; 10.17]	1.1%
Random effects model	57	134	53	130			.61; 1.73]	20.2%
Heterogeneity: $I^2 = 0\%$, $\tau^2 =$	0, p = 1.0	00						
Yearcutoff = 2018 onwar								
Bracco 2021	63	132	37	95			.84; 2.44]	14.8%
Cirillo 2021	16	21	18	30			.62; 7.38]	3.7%
Eker 2018	38	96	12	22			.21; 1.39]	6.1%
Jadhav 2019	50	73	27	64			.48; 6.00]	9.9%
Kang 2019	25	40	13	22			.40; 3.34]	4.9%
Kim 2020	36	56	5	19			58; 16.05]	4.2%
Li 2018	12	19	9	18			.46; 6.37]	3.3%
Li 2021	18	30	25	45			.47; 3.06]	6.1%
Papanagiotou 2018	177	322	66	160			.18; 2.55]	22.3%
Wallocha 2019	112	149	8	14			.74; 6.97]	4.4%
Random effects model	547	938	220	489	\$	1.68 [1	.23; 2.31]	79.8%
Heterogeneity: $I^2 = 33\%$, $\tau^2 =$	= 0.0781,	p = 0.1	5					
Random effects model	604	1072	273	619	\	1.52 [1	.19; 1.95]	100.0%
Heterogeneity: $I^2 = 15\%$, $\tau^2 = 15\%$	= 0.0332.	p = 0.29	9			•		
Test for subgroup difference	s: $\chi_1^2 = 2$.	, 53, df =	1(p = 0)	.11)	0.1 0.5 1 2 10			
5 -	201	-			against eCAS favors eCAS			
					0			

Supplementary Figure 5. Meta-analysis of proportions for recurrent stroke in eCAS group (above) and no stenting group (below).


Dalyiai et al. 2013 0 16 0.00 [0.00; 0.21] Mpotsaris et al. 2013 0 17 0.00 [0.00; 0.20] Stampfi et al. 2014 0 24 0.00 [0.00; 0.20] Tútincù et al. 2014 0 4 0.00 [0.00; 0.60] Lescher et al. 2014 0 9 0.00 [0.00; 0.34] Heck et al. 2014 0 23 0.00 [0.00; 0.05] Cohen et al. 2014 2 24 0.08 [0.01; 0.27] Lockau et al. 2014 0 37 0.00 [0.00; 0.09] Behme et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 25 0.00 [0.00; 0.08] Yoon et al. 2015 0 47 0.00 [0.00; 0.08] Steglich-Arnholm et al. 2015 0 42 0.00 [0.00; 0.08] Son et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Study			GLMM, Random, 95% CI	GLMM, Random, 95% CI
Mpotsaris et al. 2013 0 17 0.00 [0.00; 0.20] Stampfl et al. 2014 0 24 0.00 [0.00; 0.14] Tútūncū et al. 2014 0 4 0.00 [0.00; 0.60] Lescher et al. 2014 0 9 0.00 [0.00; 0.34] Heck et al. 2014 0 23 0.00 [0.00; 0.34] Heck et al. 2014 0 23 0.00 [0.00; 0.03] Lockau et al. 2014 2 24 0.08 [0.01; 0.27] Lockau et al. 2014 0 37 0.00 [0.00; 0.02] Puri et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 47 0.00 [0.00; 0.08] Yoon et al. 2015 0 42 0.00 [0.00; 0.08] Son et al. 2015 0 21 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Hajdukova et al. 2013	0	44	0.00 [0.00; 0.08]	
Stampfl et al. 2014 0 24 0.00 [0.00; 0.14] Tütüncü et al. 2014 0 4 0.00 [0.00; 0.60] Lescher et al. 2014 0 9 0.00 [0.00; 0.34] Heck et al. 2014 0 23 0.00 [0.00; 0.34] Heck et al. 2014 0 23 0.00 [0.00; 0.15] Cohen et al. 2014 2 24 0.08 [0.01; 0.27] Lockau et al. 2014 0 37 0.00 [0.00; 0.09] Behme et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 25 0.00 [0.00; 0.08] Yoon et al. 2015 0 42 0.00 [0.00; 0.08] Yoon et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]		0	16		
Tütüncü et al. 2014 0 4 0.00 [0.00; 0.60] Lescher et al. 2014 0 9 0.00 [0.00; 0.34] Heck et al. 2014 0 23 0.00 [0.00; 0.15] Cohen et al. 2014 2 24 0.08 [0.01; 0.27] Lockau et al. 2014 0 37 0.00 [0.00; 0.09] Behme et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 25 0.00 [0.00; 0.08] Yoon et al. 2015 0 47 0.00 [0.00; 0.08] Yoon et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Mpotsaris et al. 2013	0	17	0.00 [0.00; 0.20]	-
Lescher et al. 2014 0 9 0.00 [0.00; 0.34] Heck et al. 2014 0 23 0.00 [0.00; 0.15] Cohen et al. 2014 2 24 0.08 [0.01; 0.27] Lockau et al. 2014 0 37 0.00 [0.00; 0.09] Behme et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 25 0.00 [0.00; 0.08] Yoon et al. 2015 0 47 0.00 [0.00; 0.08] Son et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Stampfl et al. 2014	0	24	0.00 [0.00; 0.14]	
Heck et al. 2014 0 23 0.00 [0.00; 0.15] Cohen et al. 2014 2 24 0.08 [0.01; 0.27] Lockau et al. 2014 0 37 0.00 [0.00; 0.09] Behme et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 25 0.00 [0.00; 0.08] Steglich-Arnholm et al. 2015 0 47 0.00 [0.00; 0.08] Yoon et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Tütüncü et al. 2014	0	4	0.00 [0.00; 0.60]	P
Cohen et al. 2014 2 24 0.08 [0.01; 0.27] Lockau et al. 2014 0 37 0.00 [0.00; 0.09] Behme et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 25 0.00 [0.00; 0.02] Steglich-Arnholm et al. 2015 0 47 0.00 [0.00; 0.08] Yoon et al. 2015 0 42 0.00 [0.00; 0.08] Son et al. 2015 0 22 0.00 [0.00; 0.14] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Lescher et al. 2014	0	9	0.00 [0.00; 0.34]	
Lockau et al. 2014 0 37 0.00 [0.00; 0.09] Behme et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 25 0.00 [0.00; 0.02] Steglich-Arnholm et al. 2015 0 47 0.00 [0.00; 0.08] Yoon et al. 2015 0 42 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Heck et al. 2014	0	23	0.00 [0.00; 0.15]	
Behme et al. 2015 0 170 0.00 [0.00; 0.02] Puri et al. 2015 0 25 0.00 [0.00; 0.02] Steglich-Arnholm et al. 2015 0 47 0.00 [0.00; 0.08] Yoon et al. 2015 0 42 0.00 [0.00; 0.08] Son et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 1.00]	Cohen et al. 2014	2	24	0.08 [0.01; 0.27]	
Puri et al. 2015 0 25 0.00 [0.00; 0.14] Steglich-Arnholm et al. 2015 0 47 0.00 [0.00; 0.08] Yoon et al. 2015 0 42 0.00 [0.00; 0.08] Son et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Lockau et al. 2014	0	37	0.00 [0.00; 0.09]	
Steglich-Arnholm et al. 2015 0 47 0.00 [0.00; 0.08] Yoon et al. 2015 0 42 0.00 [0.00; 0.08] Son et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Behme et al. 2015	0	170	0.00 [0.00; 0.02]	-
Yoon et al. 2015 0 42 0.00 [0.00; 0.08] Son et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16]	Puri et al. 2015	0	25	0.00 [0.00; 0.14]	
Son et al. 2015 0 22 0.00 [0.00; 0.15] Bartolini et al. 2018 0 21 0.00 [0.00; 0.16] Total (95% CI) 2 525 0.00 [0.00; 1.00]	Steglich-Arnholm et al. 2015	0	47	0.00 [0.00; 0.08]	-
Bartolini et al. 2018 0 21 0.00 [0.00; 0.16] Total (95% CI) 2 525 0.00 [0.00; 1.00]	Yoon et al. 2015	0	42	0.00 [0.00; 0.08]	-
Total (95% Cl) 2 525 0.00 [0.00; 1.00]	Son et al. 2015	0	22	0.00 0.00; 0.15	
Total (95% Cl) 2 525 0.00 [0.00; 1.00]	Bartolini et al. 2018	0	21	0.00 [0.00; 0.16]	<mark></mark>
	Total (95% CI)			0.00 [0.00; 1.00]	
Heterogeneity: Tau ² = 22.7471; Chi ² = 0.00, df = 14 (P = 1.00); I ² = 0%	Heterogeneity: Tau ² = 22.7471	; Chi ² = 0	.00, df	= 14 (P = 1.00); I ² = 0%	

Study Mpotsaris et al. 2013 Li et al. 2018		Total 24 18	GLMM, Random, 95% Cl 0.17 [0.05; 0.37] 0.11 [0.01; 0.35]	GLMM, Random, 95% CI
Total (95% CI)	6	42	0.14 [0.07; 0.28]	0.05 0.1 0.15 0.2 0.25 0.3 0.35
Heterogeneity: Tau ² = (); Chi ² = 0	.26, df :	= 1 (P = 0.61); I ² = 0%	


Supplementary Figure 6. Embolization to new territories depending on treatment paradigm.

Study		eCAS	no ster Events	-	Odds Ratio	OR	95%-CI	Weight
oludy	Lventa	Total	Lvents	lotai	odds Ratio		30 //-CI	Weight
Bracco 2021	36	132	2	95		17.44	[4.08; 74.50]	33.5%
Li 2018	3	19	5	18		0.49	[0.10; 2.43]	32.7%
Li 2021	3	30	10	45		0.39	[0.10; 1.55]	33.8%
Random effects model Heterogeneity: $I^2 = 89\%$, τ		181 ס < 0.	17	158		1.50	[0.12; 19.39]	100.0%
		,			0.1 0.5 1 2 10 favors eCAS against eCAS			

Supplementary Figure 7. Meta-analysis of proportions for restenosis after eCAS and no stenting




Supplementary Figure 8. Successful reperfusion (TICI 2b-3) prevalence depending on antegrade (stenting first) vs retrograde (mechanical thrombectomy, MT, first) in eCAS group.




Supplementary Figure 9. mRS 0-2 prevalence depending on antegrade (stenting first) vs retrograde (mechanical thrombectomy, MT, first) in eCAS group.

Source	OR (95% CI)
Bracco 2021	1.00 [0.51; 1.99]
Eker 2018	1.33 [0.63; 2.81]
Kang 2019	0.69 [0.15; 3.10]
Lockau 2014	0.46 [0.11; 1.94]
Maus 2018	0.89 [0.46; 1.71]
Mpotsaris 2017	0.38 [0.12; 1.26]
Puri 2015	1.25 [0.07; 23.26]
Rangel-Castilla 2017	0.62 [0.07; 5.97]
Total	0.88 [0.62; 1.25]
Heterogeneity: $\chi_7^2 = 4.20$	$O(P = .76), I^2 = 0\%$



Supplementary Figure 10. sICH prevalence depending on use of antithrombotics in eCAS group.



Supplementary Figure 11. mRS 0-2 prevalence depending on use of antithrombotics in eCAS group.

